Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Author's Avatar
Mar 17, 2022

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021